Search research articles
Contact Us
Filters
Showing results (211-220 of 302) with videos related to
Page
of 31
Sort By:
Breast Cancer Research and Treatment
|
October 24, 2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S Sonke, Lowell L Hart, Mario Campone, et al.
Breast Cancer Research and Treatment
|
October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Nature Medicine
|
January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Pierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
Targeted Oncology
|
November 20, 2012
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial
Christophe Le Tourneau, Maud Kamal, Olivier Trédan, et al.
JCO Global Oncology
|
February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Concetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
The Lancet. Oncology
|
February 11, 2014
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice André, Thomas Bachelot, Frederic Commo, et al.
The Oncologist
|
May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial
Bruno Coudert, Bernard Asselain, Mario Campone, et al.
Journal of the National Cancer Institute
|
September 3, 2025
Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort
Daniele Presti, Antonio Di Meglio, Julie Havas, et al.
Breast Cancer Research and Treatment
|
December 24, 2013
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2
J Thaddeus Beck, Gabriel N Hortobagyi, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
Henri Roché, Pierre Fumoleau, Marc Spielmann, et al.
Page
of 31
Search research articles
Search
Showing results (211-220 of 302) with videos related to
Sort By:
Page
of 31
Breast Cancer Research and Treatment
|
October 24, 2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S Sonke, Lowell L Hart, Mario Campone, et al.
Breast Cancer Research and Treatment
|
October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Nature Medicine
|
January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Pierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
Targeted Oncology
|
November 20, 2012
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial
Christophe Le Tourneau, Maud Kamal, Olivier Trédan, et al.
JCO Global Oncology
|
February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Concetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
The Lancet. Oncology
|
February 11, 2014
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
Fabrice André, Thomas Bachelot, Frederic Commo, et al.
The Oncologist
|
May 22, 2012
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial
Bruno Coudert, Bernard Asselain, Mario Campone, et al.
Journal of the National Cancer Institute
|
September 3, 2025
Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort
Daniele Presti, Antonio Di Meglio, Julie Havas, et al.
Breast Cancer Research and Treatment
|
December 24, 2013
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2
J Thaddeus Beck, Gabriel N Hortobagyi, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
Henri Roché, Pierre Fumoleau, Marc Spielmann, et al.
Page
of 31